ProterixBio Inc (ProterixBio), formerly BioScale Inc, is a medical device company that develops chronic care platforms for chronic respiratory diseases. The company is developing a chronic care platform for chronic obstructive pulmonary disease. ProterixBio also focuses on other medical areas including CF (cystic fibrosis) and IPF (idiopathic pulmonary fibrosis). It serves biopharmaceutical companies, academic institutions and government laboratories, among others. BioScale is headquartered in Billerica, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company ProterixBio Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
ProterixBio Inc Company Overview
ProterixBio Inc Company Snapshot
ProterixBio Inc Pipeline Products and Ongoing Clinical Trials Overview
ProterixBio Inc – Pipeline Analysis Overview
ProterixBio Inc - Key Facts
ProterixBio Inc - Major Products and Services
ProterixBio Inc Pipeline Products by Development Stage
ProterixBio Inc Pipeline Products Overview
Disease Management Tool - CF
Disease Management Tool - CF Product Overview
Disease Management Tool - COPD
Disease Management Tool - COPD Product Overview
Disease Management Tool - IPF
Disease Management Tool - IPF Product Overview
ProterixBio Inc - Key Competitors
ProterixBio Inc - Key Employees
ProterixBio Inc - Locations And Subsidiaries
Head Office
Recent Developments
ProterixBio Inc, Recent Developments
Feb 08, 2023: ProterixBio announces commercial offering of quantitative soluble ST2 assay
Feb 12, 2021: ProterixBio commercially launches serology test for Covid-19
Sep 29, 2020: ProterixBio announces commercial availability of a semi-quantitative COVID-19 antibody test
May 22, 2018: ProterixBio Presents Results from Multiple COPD Clinical Studies at the American Thoracic Society International Conference
Sep 12, 2017: ProterixBio presents COPD clinical study results at the European Respiratory Society International Congress
Sep 13, 2016: ProterixBio Joins the Industrial Advisory Boards of the COPD Foundation and the SPIROMICS Consortium
Jul 28, 2016: ProterixBio and the University of Zurich Receive Michael J. Fox Foundation Grant to Develop a Novel Assay for Alpha-synuclein Aggregates
Jul 13, 2016: ProterixBio Announces the Appointment of Dr. Fernando Martinez to its Scientific Advisory Board
May 03, 2016: BioScale Announces Company Name Change to ProterixBio and New Focus on Pulmonary Diagnostics and Disease Management
May 25, 2015: BioScale introduces new ViBE software v3